NCT00626366 is a NA clinical trial of Sinus CT Scan in Chronic Sinusitis, sponsored by University of Nebraska.

Who is sponsoring NCT00626366?

NCT00626366 is sponsored by University of Nebraska.

What drugs are being tested in NCT00626366?

Interventions in NCT00626366: Sinus CT Scan, Omnipaque 240 Contrast Solution, Omnipaque 240 mg I/mL.

What condition does NCT00626366 study?

NCT00626366 studies Chronic Sinusitis.

Is NCT00626366 still recruiting?

NCT00626366 is currently completed. Last updated 28 September 2023.

Are results published for NCT00626366?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-09-28 · How we verify

NCT00626366

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison

Completed NA Results posted Last updated 28 September 2023

What this trial tests

NA trial testing Sinus CT Scan in Chronic Sinusitis in 18 participants. Completed in 9 January 2009.

Timeline

12 March 2008

Primary endpoint
9 January 2009

9 January 2009

Quick facts

Lead sponsor	University of Nebraska
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	single
Primary purpose	other
Enrollment	18
Start date	12 March 2008
Primary completion	9 January 2009
Estimated completion	9 January 2009
Sites	1 location across United States

Drugs / interventions tested

Sinus CT Scan
Omnipaque 240 Contrast Solution — full drug profile →
Omnipaque 240 mg I/mL — full drug profile →

Conditions studied

Chronic Sinusitis — all drugs for Chronic Sinusitis →

Sponsor

University of Nebraska

Who can join

19 and older, any sex, with Chronic Sinusitis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

To Measure the Distribution of Nasal Sprays and Drops. Primary · 2 months

CT scan scored for distribution contrast delivered by nasal spray or drops within subsets in the nasal cavity. The sinonasal cavity was divided into twenty-one subsites on each side of the nasal cavity. The interpreters scored for the presence (1) or absence (0) of contrast from the nasal spray or nasal drops within each subsite. Left and right sides were interpreted separately for a possible total score of 0-42 for each CT scan.

Nasal vestibule

Group	Value	95% CI
Nasal Spray	18
Nasal Drops	17

Inferior upper nasal vault

Group	Value	95% CI
Nasal Spray	16
Nasal Drops	17

Superior upper nasal vault

Group	Value	95% CI
Nasal Spray	0
Nasal Drops	6

Anterior floor of nose

Group	Value	95% CI
Nasal Spray	12
Nasal Drops	4

Anterior inferior meatus

Group	Value	95% CI
Nasal Spray	16
Nasal Drops	0

Anterior inferior nasal cavity

Group	Value	95% CI
Nasal Spray	15
Nasal Drops	6

Posterior floor of nose

Group	Value	95% CI
Nasal Spray	9
Nasal Drops	0

Posterior inferior meatus

Group	Value	95% CI
Nasal Spray	9
Nasal Drops	1

Sponsor's own description

The purpose of this study is to determine the distribution of nasal sprays and nasal drops when used.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Nebraska trials

Trials by the same sponsor.

NCT07507006 — Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance · NA · not yet recruiting
NCT07517705 — MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma · NA · not yet recruiting
NCT07506993 — Inflammation in Clear Aligners With and Without Attachments · not yet recruiting
NCT07207850 — Parents Helping Parents for Youth Vaping Cessation · NA · not yet recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00626366 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nebraska
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00626366.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing